LDCA
Based on 1 Customer Validation
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression.
For research use only. We do not sell to patients.
- Purity: 98.66%
- CAS No.: 349106-80-5
- Formula: C8H5Cl3FNO
- Molecular Weight:256.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
LDCA (2-100 μM; 16-72 h) is used in combination with doxorubicin synergistically, enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B16-F10 cells
-
Concentration:2-100 μM
-
Incubation Time:72 h
-
Result:Arrested cell growth with a dose-dependent cytotoxic effect and had a strong synergism with LDCA.
-
Cell Line:B16-F10 cells
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Resulted 15% death when cells exposed to LDCA and caused 40% melanoma cell death combination synergistically with doxorubicin.
-
Cell Line:B16-F10 cells
-
Concentration:20 μM
-
Incubation Time:16 h
-
Result:Demonstrated that combination with doxorubicin resultantly affected cellular morphology with condensed and fragmented nuclei.
-
Cell Line:B16-F10 cells
-
Concentration:20 μM
-
Incubation Time:16 h
-
Result:Signicantly limited the migratory potential in the B16-F10 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:melanoma tumor model[1]
-
Dosage:2 mg/kg
-
Administration:2 mg/kg, iv., the 6th day, once
-
Result:Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena.
Chemical Information
-
CAS No. 349106-80-5
-
Appearance Solid
-
Molecular Weight 256.49
-
Formula C8H5Cl3FNO
-
Color Light yellow to yellow
-
SMILES
FC1=C(Cl)C=C(NC(C(Cl)Cl)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (389.88 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8988 mL | 19.4939 mL | 38.9879 mL | 97.4697 mL |
| 5 mM | 0.7798 mL | 3.8988 mL | 7.7976 mL | 19.4939 mL | |
| 10 mM | 0.3899 mL | 1.9494 mL | 3.8988 mL | 9.7470 mL | |
| 15 mM | 0.2599 mL | 1.2996 mL | 2.5992 mL | 6.4980 mL | |
| 20 mM | 0.1949 mL | 0.9747 mL | 1.9494 mL | 4.8735 mL | |
| 25 mM | 0.1560 mL | 0.7798 mL | 1.5595 mL | 3.8988 mL | |
| 30 mM | 0.1300 mL | 0.6498 mL | 1.2996 mL | 3.2490 mL | |
| 40 mM | 0.0975 mL | 0.4873 mL | 0.9747 mL | 2.4367 mL | |
| 50 mM | 0.0780 mL | 0.3899 mL | 0.7798 mL | 1.9494 mL | |
| 60 mM | 0.0650 mL | 0.3249 mL | 0.6498 mL | 1.6245 mL | |
| 80 mM | 0.0487 mL | 0.2437 mL | 0.4873 mL | 1.2184 mL | |
| 100 mM | 0.0390 mL | 0.1949 mL | 0.3899 mL | 0.9747 mL |
LDCA Related Classifications
HY-147361 Related Classifications
Powered by Bioz